An interventional study of Therapeutic Intra-Vascular UltraSound (TIVUS™) System in Pulmonary Arterial Hypertension, sponsored by SoniVie Inc.. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-21.
Sponsored by SoniVie Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 313 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.
Among the 313 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 190th largest by planned enrollment of the 253 interventional ones that give a count, is one of 15 that started in 2017, is one of 26 with no phase, reaches primary completion later than 1 of the 55 other live ones, and was the 168th registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →38 of the 313 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
35Pharma Inc., a GSK company · Sites in United States, Spain, United Kingdom
Ages 18+
Insmed Incorporated · Sites in United States, Argentina, Australia and 5 more countries
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
313 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 94 · Phase 3 73 · Phase 4 33
First in 2002; this study’s year is marked. 15 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 40 across the 253 interventional studies, 59 across the 60 observational. Of the 235 that completed or were terminated, 133 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
186 of 313 have an industry lead sponsor. The 10 most frequent:
SoniVie Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
SoniVie Inc. has 3 studies filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
18 of the studies in Pulmonary Arterial Hypertension with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06274801Phase 3Gossamer Bio USA, Inc.Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | 2026-12 |
| NCT05649748Phase 3Insmed IncorporatedAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | 2026-12-31 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT07312227Massachusetts General HospitalA Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 313 studies in Pulmonary Arterial Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the safety, performance and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation through subjective and objective change in clinical parameters and haemodynamic evaluation. This is a prospective, multi-center, non-randomized, open-label clinical trail. The study will be conducted in up to 4 centers and will recruit up to 15 patients diagnosed with PAH, functional class III who have stable PAH on a stable drug regimen of two pulmonary arterial hypertension specific medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
Device: Therapeutic Intra-Vascular UltraSound (TIVUS™) System
The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation. Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation.
Also known as: TIVUS™
Amount of all procedural related adverse event as assessed by the CEC
Procedural related Adverse Events
Time frame: 1 month
Amount of treatment related adverse event as assessed by the CEC
All treatment related adverse events
Time frame: 12 month
Number of patient with PAH worsening and all cause death events
PAH related adverse events and all cause death
Time frame: 12 month
Clinical effectiveness
Changes from baseline of mean pulmonary arterial pressure (mPAP)
Time frame: 6 months
Clinical effectiveness
Changes from baseline of pulmonary vascular resistance (PVR)
Time frame: 6 months
Clinical effectiveness
Changes from baseline of 6 minute walking distance (6MWD)
Time frame: 6 months
Clinical effectiveness
Changes from baseline of quality of life questionaire
Time frame: 6 months
Clinical effectiveness
NT-pro-BNP levels
Time frame: 1, 6 and 12 months
Clinical efffectivness
Change from baseline in Right Ventricular (RV) function as assesed by MRI
Time frame: 6 months
Clinical efffectivness
Change from baseline in Right Ventricular (RV) function as assesed by Echocardiography
Time frame: 6 months
Observational Variables
Changes from baseline of mean pulmonary arterial pressure (mPAP)
Time frame: 12 Months
Observational Variables
Changes from baseline of pulmonary vascular resistance (PVR)
Time frame: 12 Months
Observational Variables
Changes from baseline of 6 minute walking distance (6MWD)
Time frame: 12 Months
Observational Variables
Changes from baseline of quality of life questionaire
Time frame: 12 Months
Observational Variables - Long term surveillance
Clinical change of pulmonary arterial hypertension condition defined by patient survival or cause of mortality
Time frame: 2, 3, 4 and 5 years
Observational Variables - Long term surveillance
Clinical change of pulmonary arterial hypertension condition defined by hospitalization due to pulmonary arterial hypertension
Time frame: 2, 3, 4 and 5 years
Observational Variables - Long term surveillance
Clinical change of pulmonary arterial hypertension condition defined by any intervention or surgical procedures the patient did
Time frame: 2, 3, 4 and 5 years
Observational Variables - Long term surveillance
Clinical change of pulmonary arterial hypertension condition defined by worsening of WHO functional class
Time frame: 2, 3, 4 and 5 years
Observational Variables - Long term surveillance
Clinical change of pulmonary arterial hypertension condition defined by escalation of drug therapy
Time frame: 2, 3, 4 and 5 years
Observational Variables
Echocardiography parameters
Time frame: 12 month
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2017 to primary completion in Apr 2019, 25 months.
Of 65 interventional studies with no phase under Pulmonary Arterial Hypertension, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
SoniVie Inc.